Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA) Stock Price

KNSAStock

$78.59+101.93%52W

Market Cap$6.05B

P/E103.92x

PEG Ratio—

Div yield—

Beta0.12

KNSA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)57.59%

Price vs S&P 500 (4W)1.91%

VGM Score65.12

P/E Ratio (Annual)103.92x

P/CF (Annual)44.44x

Book Value / Share (Quarterly)$8.38

P/TBV (Annual)5.66x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)45.45%

Cash Flow / Share (Quarterly)$2.34

Price vs S&P 500 (YTD)78.59%

Gross Margin (TTM)89.82%

Net Profit Margin (TTM)9.59%

EPS (TTM)$0.98

10-Day Avg Trading Volume0.55M

EPS Excl Extra (TTM)$0.98

EPS (Annual)$0.75

ROI (Annual)10.40%

Gross Margin (Annual)88.54%

Net Profit Margin (5Y Avg)-64.55%

Cash / Share (Quarterly)$6.74

P/E Basic Excl Extra (TTM)76.02x

Revenue Growth QoQ (YoY)55.36%

P/E Normalized (Annual)103.92x

ROA (Last FY)7.73%

Revenue Growth TTM (YoY)58.85%

EBITD / Share (TTM)$1.25

ROE (5Y Avg)-7.06%

Operating Margin (TTM)11.92%

Cash Flow / Share (Annual)$1.79

P/B Ratio9.37x

P/B Ratio (Quarterly)7.52x

Net Income / Employee (Annual)$161,200

EV / Revenue (TTM)7.08x

ROA (TTM)10.09%

EPS Growth QoQ (YoY)33.26%

EV / EBITDA (TTM)58.37x

EPS Incl Extra (Annual)$0.75

Current Ratio (Annual)3.79x

Quick Ratio (Quarterly)3.21x

3-Month Avg Trading Volume0.69M

52-Week Price Return101.93%

EV / Free Cash Flow (Annual)43.66x

P/E Incl Extra (TTM)76.02x

Revenue / Employee (TTM)$2,297,400

Tangible BV / Share (Quarterly)$8.19

P/S Ratio (Annual)9.05x

Asset Turnover (Annual)0.89x

52-Week High$82.98

Operating Margin (5Y Avg)-82.13%

EPS Excl Extra (Annual)$0.75

CapEx CAGR (5Y)41.14%

Tangible BV CAGR (5Y)65.91%

26-Week Price Return67.50%

Quick Ratio (Annual)3.09x

13-Week Price Return22.89%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.90x

Enterprise Value$5.96B

Asset Turnover (TTM)1.05x

Book Value / Share Growth (5Y)10.21%

Revenue / Employee (Annual)$1,851,300

Inventory Turnover (Annual)1.91x

Pretax Margin (Annual)13.12%

Cash / Share (Annual)$5.43

3-Month Return Std Dev57.07%

Gross Margin (5Y Avg)85.56%

Net Income / Employee (TTM)$220,400

ROE (Last FY)10.40%

EPS Basic Excl Extra (Annual)$0.75

P/FCF (TTM)33.54x

Receivables Turnover (TTM)30.36x

EV / Free Cash Flow (TTM)32.58x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$0.98

Receivables Turnover (Annual)23.64x

ROI (TTM)13.65%

P/S Ratio (TTM)7.29x

Pretax Margin (5Y Avg)-80.54%

Revenue / Share (Annual)$8.58

Tangible BV / Share (Annual)$7.24

Forward P/E48.07x

Price vs S&P 500 (52W)86.40%

P/E Ratio (TTM)76.02x

EPS Growth TTM (YoY)2297.07%

Year-to-Date Return90.52%

5-Day Price Return-0.82%

EPS Normalized (Annual)$0.75

ROA (5Y Avg)-5.00%

Net Profit Margin (Annual)8.71%

Month-to-Date Return5.33%

Cash Flow / Share (TTM)$-0.06

EBITD / Share (Annual)$1.00

EPS Growth (3Y)-34.04%

Operating Margin (Annual)11.40%

P/CF (TTM)33.15x

ROI (5Y Avg)-7.06%

P/E Excl Extra (TTM)76.02x

EPS Basic Excl Extra (TTM)$0.98

P/TBV (Quarterly)7.70x

P/B Ratio (Annual)5.51x

Inventory Turnover (TTM)1.44x

Pretax Margin (TTM)13.59%

Book Value / Share (Annual)$7.44

Price vs S&P 500 (13W)20.21%

Beta0.12x

P/FCF (Annual)44.95x

Revenue / Share (TTM)$10.08

ROE (TTM)13.65%

52-Week Low$35.20

vGradeD

gGradeB

mGradeA

vgmGradeB

KNSA Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Jul 28, 2026	$0.28	$0.30	+5.26%(+$0.02)
Q1 2026	Apr 28, 2026	$0.16	$0.27	+68.75%(+$0.11)
Q4 2025	Feb 24, 2026	$0.40	$0.17	-57.29%(-$0.23)
Q3 2025	Oct 28, 2025	$0.37	$0.23	-37.28%(-$0.14)
Q2 2025	Jul 29, 2025	$0.26	$0.23	-11.30%(-$0.03)

KNSA Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.29

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78
MIRMMirum Pharmaceuticals, Inc. Common Stock	F	B	C	8.4x	44.0%	81.7%	—	$80.14

About Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares

Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for cardiovascular diseases. Its pipeline includes three lead candidates: Rilonacept, abiprubart, and Vixarelimab, with primary operations in the United States.

KNSA Next Earnings Report

Report dateOct 27, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate$0.32

Revenue estimate$260.16M

Also reporting on Oct 27, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for October 2026

KNSA Insider Transactions

SellSep 3, 2026
MEGNA MICHAEL R
Officer
Shares: 4,600Value: $369,380
SellJul 29, 2026
COLE GORDON BRADLEY
Director
Shares: 3,673Value: $299,092

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

ELFe.l.f. Beauty, Inc.Cosmetics & Toiletries
LNTHLantheus Holdings, IncIn Vitro Diagnostics
ICLICL Group Ltd.Agricultural Chemicals
IOVAIovance Biotherapeutics, Inc. Common StockBiological Products
MOSThe Mosaic CompanyAgricultural Chemicals
SXTSensient Technology CorporationIndustrial Chemicals
IMVTImmunovant, Inc. Common StockBiological Products
BCPCBalchem CorporationChemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.3

Strong Buy

Consensus rating

52-Week Range

Low$35.20

High$82.98